Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAkari Therapeutics PLC

Akari Therapeutics PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
7.4 USD 0.03 ( 0.41%)
Last update at 2026-11-09T15:39:00Z
VOLUME
8887
Market Cap
19.96M

Momentum Score

…

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.40
Low
7.89
High
52 Week Price Range
3.02
Low
49.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Akari Therapeutics plc is a clinical-stage biopharmaceutical company developing complement and immune-modulating therapies, with lead candidate nomacopan, a dual inhibitor of complement C5 and leukotriene B4, intended for rare and severe inflammatory disorders. Major long-term growth drivers include successful clinical development and regulatory approvals in orphan indications, potential label expansion into additional complement-mediated diseases, and partnerships or commercialization outcomes. Investors may find exposure to a differentiated dual-mechanism candidate addressing unmet needs in high-cost rare disease markets attractive.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.37
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.03
ROE
-140.09%
Net Debt
-4.45M
ROCE
-48.61%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -18.30M -19.79M -10.01M -17.75M -17.42M
Net income -17.30M -19.79M -10.01M -6.97M -17.61M
Selling general administrative 9.28M 9.66M 11.36M 13.53M 8.08M
Selling and marketing expenses - - 11.34M - -
Gross profit - -0.01M -0.00M - -
Reconciled depreciation 0.00M 0.01M 0.00M 0.00M 0.00M
Ebit - -19.55M -16.81M -23.09M -17.21M
Ebitda -17.27M -19.53M -16.80M -28.52M -17.02M
Depreciation and amortization - 0.01M 0.00M -5.43M 0.20M
Operating income -17.27M -21.64M -16.81M -23.09M -17.21M
Other operating expenses 17.27M 21.64M 16.81M 23.09M 17.21M
Interest expense 0.95M 0.24M 0.00M -5.34M 0.21M
Tax provision -1.00M 0.00M - -2.47M -
Interest income 0.00M 0.01M 0.08M 0.05M 0.01M
Net interest income -0.95M -0.24M 0.08M 0.05M 0.01M
Income tax expense -1.00M - - -10.78M 0.18M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 17.27M 21.64M 16.81M 23.89M 17.21M
Cost of revenue - 0.01M 0.00M - -
Total other income expense net -1.03M 1.85M 6.80M 5.34M -0.21M
Net income from continuing ops -17.30M -19.79M -10.01M -17.75M -17.42M
Net income applicable to common shares - - - - -17.42M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 47.89M 50.56M 4.36M 13.83M 11.65M
Intangible assets 34.00M 39.18M 0.01M 0.02M 0.02M
Other current assets 0.26M 0.15M 0.50M 0.10M 0.09M
Total liab 19.56M 28.33M 4.58M 12.04M 6.09M
Total stockholder equity 28.33M 22.23M -0.23M 1.79M 5.55M
Other current liab 2.83M 4.24M 2.91M 11.09M 4.30M
Common stock - 5.32M 1.32M 0.74M 0.48M
Capital stock 0.00M 5.32M - 0.74M 0.48M
Retained earnings -264.55M -247.25M -227.46M -217.45M -199.71M
Good will 8.43M 8.43M - - -
Cash 5.20M 2.60M 3.85M 13.25M 9.36M
Total current liabilities 12.35M 19.91M 4.58M 12.04M 6.09M
Net debt -4.45M 0.66M -3.85M -13.25M -9.36M
Short term debt 0.75M 3.26M - - -
Short long term debt 0.75M 3.26M - - -
Short long term debt total 0.75M 3.26M - - -
Other stockholder equity 293.66M 264.90M 174.75M 219.27M 205.32M
Total current assets 5.46M 2.95M 4.34M 13.81M 11.63M
Net tangible assets - - - - 5.53M
Net receivables - 0.20M - 2.95M -
Inventory - - - -2.49M -
Accounts payable 8.77M 12.41M 1.67M 0.95M 1.79M
Accumulated other comprehensive income -0.78M -0.74M 51.15M -0.77M -0.54M
Non currrent assets other - - 0.01M - -
Non current assets total 42.43M 47.61M 0.01M 0.02M 0.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.38M 0.00M - -
Change to liabilities - - - - -0.24M
Total cashflows from investing activities - 0.38M - - -
Net borrowings 1.05M -0.85M 0.00M - -
Total cash from financing activities 13.17M 10.99M 7.02M 25.29M 14.29M
Change to operating activities - - - - -1.74M
Net income -17.30M -19.79M -10.01M -17.75M -17.42M
Change in cash 2.60M -1.19M -9.40M 3.89M -4.69M
Begin period cash flow 2.66M 3.85M 13.25M 9.36M 14.06M
End period cash flow 5.26M 2.66M 3.85M 13.25M 9.36M
Total cash from operating activities -10.57M -12.55M -16.43M -21.50M -18.85M
Issuance of capital stock 10.72M 11.81M 7.02M 25.19M 14.29M
Depreciation 0.00M 0.01M 0.00M 0.00M 0.00M
Other cashflows from investing activities - 0.38M - - -
Change to account receivables - - - 1.70M -
Other cashflows from financing activities 13.17M 0.03M 0.00M 0.09M -
Change to netincome - - - - 0.56M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.40M 6.54M -0.87M 0.82M -1.98M
Stock based compensation 2.89M 2.25M 1.15M 0.74M 0.31M
Other non cash items 5.33M -1.56M -6.71M -5.32M 0.24M
Free cash flow -10.57M -12.55M -16.43M -21.50M -18.85M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AKTX
Akari Therapeutics PLC		 0.03
0.41%		 7.40 - - 478368.50 1.17 400346.36 -0.06
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Akari Therapeutics PLC

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

401 East Jackson Street, Tampa, FL, United States, 33602

929 274 7510

https://www.akaritx.com

5

Name Title Year Born
Dr. Ray Prudo-Chlebosz M.D. Exec. Chairman 1945
Dr. Torsten Hombeck Chief Financial Officer 1970
Ms. Rachelle Suzanne Jacques Pres, CEO & Director 1971
Ms. Melissa Bradford-Klug Chief Operating Officer NA
Dr. Miles Nunn Chief Scientific Officer NA
Dr. John F. Neylan III, M.D. Exec. VP & Chief Medical Officer 1953
Annie Mack Financial Controller NA
Ms. Rachelle Suzanne Jacques President, CEO & Director 1971
Ms. Wendy F. DiCicco CPA Interim Chief Financial Officer 1967
Ms. Melissa Bradford-Klug Chief Operating Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…